Reynoso Jamie L. sold $18K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 4,066 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.41 on 2026-10-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Oct 20, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

A modest insider sell may cause short‑term price softness, but the overall impact is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The CEO's holdings remain large, and the sale was pre‑arranged under a 10b5‑1 plan, reducing the perceived informational value.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CLOVBearishHigh confidence
Context

CEO Reynoso Jamie L. sold 4,066 shares for $17,931 via a 10b5‑1 plan, reducing his stake to 2,770,351 shares.

Expected impact

likely slight downward pressure as investors digest the sell‑off

Evidence & confidence

A 10b5‑1 sale by the CEO, even at a modest $18K, can be interpreted as a lack of confidence, though the size is negligible compared with total holdings.

Market effects

Minimal impact on the health‑tech sector; the sale is company‑specific.

No broader regional effect; confined to CLOV shareholders.

Insignificant on a global scale.

Counterpoint

The sale could be routine liquidity management rather than a negative signal.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Reynoso Jamie L.

    CEO of Clover Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.